Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: AstraZeneca/Vanderbilt, Medicago, OcellO/Merus

Executive Summary

High-level executive changes at AstraZeneca continue pondering of where the British pharma turns next for growth – will it look to large-scale M&A again?

You may also be interested in...



Deals Of The Week: Wondering Where Have The Private Biotech Take-Outs Gone?

M&A has slowed for private biotechs this year, as acquisitions are overshadowed by IPOs. AstraZeneca is one of the few big biopharmas actively buying private biotechs. An option-to-acquire deal structure, amply employed by Celgene, is popping up lately.

AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later

AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.

AstraZeneca Teams With Vanderbilt In Neuroscience Pact

Vanderbilt University’s neuroscience research group reaches its latest agreement with a pharma, this one covering compounds that treat symptoms of Alzheimer’s disease and schizophrenia by modulating a receptor in new ways.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel